Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 96
- Registration Number
- NCT01768858
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 776
- Registration Number
- NCT01764997
- Locations
- 🇺🇸
Investigational Site Number 840203, Washington, D.C., District of Columbia, United States
🇦🇷Investigational Site Number 032009, Zarate, Argentina
🇨🇱Investigational Site Number 152018, Santiago, Chile
Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 346
- Registration Number
- NCT01736189
Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
- Conditions
- Interventions
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Alimentiv Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01716039
A Study in Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1307
- Registration Number
- NCT01710358
- Locations
- 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸The Seattle Arthritis Clinic, Seattle, Washington, United States
🇺🇸Valley Arthritis Care, LLC, Phoenix, Arizona, United States
Swiss Dermatology Network of Targeted Therapies (SDNTT)
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Swiss Dermatology Network for Targeted Therapies
- Target Recruit Count
- 1121
- Registration Number
- NCT01706692
- Locations
- 🇨🇭
Aarau Cantonal Hospital, Aarau, Switzerland
🇨🇭Inselspital - Bern University Hospital, Bern, Switzerland
🇨🇭Basel University Hospital, Basel, Switzerland
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 417
- Registration Number
- NCT01695239
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, United Kingdom
Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Peter Higgins
- Registration Number
- NCT01674413
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Adalimumab in the Treatment of Chronic Pouchitis
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT01670240
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
Adalimumab for the Management of Post-operative Crohn's Disease (CD)
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01629628
- Locations
- 🇮🇱
Department of Gastroenterology and Liver Diseases, Tel-Aviv Soursky Medical Center, Tel-Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.